BioSpace News Archive

AbbVie and AbCellera inked an antibody discovery deal to develop candidates for up to five targets in several indications.

Third Harmonic Bio drops its Phase 1b asset.

BioCryst Pharmaceuticals is discontinuing the development of its Factor D inhibitor BCX9930 in paroxysmal nocturnal hemoglobinuria due to competitive factors.

In a strategic reorganization announced Thursday, Axcella Therapeutics will focus its resources on its Long COVID program and slash headcount by 85%.

Infermedica today reflects on the major milestones it has achieved throughout 2022 and looks forward to its continued growth in the new year.

Pharming Group N.V. announces data, including new evidence, from an interim analysis of its open-label extension study evaluating the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta inhibitor, to treat adult and adolescent patients with activated phosphoinositide 3-kinase delta syndrome, a rare primary immunodeficiency.

AlzeCure Pharma AB announced that an abstract with new preclinical Alzstatin data has been accepted for presentation at the Alzheimer conference AD/PD 2023, which will be held in Gothenburg, Sweden, on March 28 - April 1.

XNK Therapeutics AB announced that the first patient has donated cells in the recently initiated preclinical evaluation of the autologous NK cell product XNK03 in locally advanced or metastatic urothelial cancer.

Comanche Biopharma announced that maternal health, vaccine and drug development expert Allison August, M.D., has been appointed as the company´s Chief Medical Officer.

Reviva Pharmaceuticals Holdings, Inc. today announced positive data from its recently completed clinical drug-drug interaction (DDI) study investigating the potential effect of CYP3A4 enzyme on brilaroxazine in healthy subjects.